|
| HER2低表达乳腺癌的诊治现状和临床启示 |
| Current situation and clinical implications of HER2 low expression in breast cancer |
| 投稿时间：2026-01-06 修订日期：2026-03-13 |
| DOI： |
|
 |
| 中文关键词: 乳腺癌 HER2低表达 免疫组织化学 抗体-药物偶联物 曲妥珠单抗德鲁替康 |
| 英文关键词:Breast cancer HER2 low expression immunohistochemistry antibody-drug conjugate trastuzumab deruxtecan |
| 基金项目:课题编号:2025DA068；课题名称:MFAP1 K324乳酰化调控乳腺癌发生发展及湛江弓果藤抗乳腺癌 ；研究类别:兵团科技项目 |
|
| 摘要点击次数: 68 |
| 全文下载次数: 0 |
| 中文摘要: |
| 乳腺癌是全球女性最常见的恶性肿瘤之一。根据HER2表达水平,传统上将乳腺癌分为HER2阳性和HER2阴性两类。近年来,研究发现部分传统HER2阴性的患者实际存在HER2低表达(免疫组织化学评分1+或2+,但原位杂交阴性)的情况,这类患者以往未能从HER2靶向治疗中获益,但新型抗体-药物偶联物(ADC)如曲妥珠单抗德鲁替康(T-DXd)的出现为其提供了新的治疗选择。本文围绕HER2低表达乳腺癌的概念、诊断标准和检测方法的一致性问题,系统总结其临床病理特征、预后意义以及当前针对HER2低表达乳腺癌患者的治疗研究进展,并提出未来应在标准化检测、临床疗效评估和真实世界研究等方面加强探索,为临床决策提供依据。 |
| 英文摘要: |
| Breast cancer is one of the most common malignancies affecting women globally. Traditionally, it has been classified into HER2-positive and HER2-negative subtypes based on HER2 expression levels. Recent studies have revealed that some patients previously categorized as HER2-negative actually exhibit HER2 low expression (immunohistochemical scores of 1+ or 2+, but negative for in situ hybridization). These patients, who were previously excluded from HER2-targeted therapies, now gain access to novel treatment options through innovative antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd). This article systematically examines the clinical-pathological characteristics, prognostic implications, and current therapeutic advancements for HER2-low breast cancer. It addresses key challenges including standardizing testing protocols, improving clinical efficacy evaluation, and conducting real-world research to inform clinical decision-making. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|